Biotech Support Group LLC Files Patent Application for New Cancer Serum Biomarker Panel Called Stroma Liquid Biopsy™

Monmouth Junction, N.J. May 23, 2018

Biotech Support Group announced today that it has filed a patent application for Stroma Liquid Biopsy™, a biomarker panel of cancer dysregulation derived from blood. The patent was filed on April 13, 2018 and was titled “Monitoring Dysregulated Serum Complement, Coagulation, and Acute-Phase Inflammation Sub-Proteomes Associated with Cancer”. U.S. Patent Application No. is 15/953,260.

In summary, Stroma Liquid Biopsy™ offers methods to monitor and potentially modulate the systemic response to cancer, offering new avenues for early detection, personalized medicine and therapeutic modalities. This is groundbreaking in the medical field where there still remains a significant unmet need for biomarkers reportable in blood that can profile each person’s unique physiological response to cancer.

According to Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group, “These are very exciting developments as we now have methods to monitor the influence of an overlooked protein family – the SERPINs. This is a fundamentally new way to think about molecular regulation in blood from a cancer patient. Our patent application describes an imbalance in this family, and by characterizing this dysregulation in cancer, new avenues for early diagnosis, personalized medicine, and therapeutic modalities will be forthcoming.”

Stroma Liquid Biopsy™ identifies 12 blood proteins differentially observed from 5 primary tumors of origin and all clinical stages of cancer. The unique significance of this pan-cancer profile is that this dysregulation was categorically intertwined with the most rudimentary needs of cancer: space, nutrients and immune evasion. Moreover, the changes within the biomarker panel all occur within an interdependent network of cascading protein transformational events, known as proteolysis. Proteolysis is irreversible, and because it is irreversible, all species of life have evolved molecular regulatory systems to control aberrancies. The most distinguished is a protein family of regulators known as SERPINs.

Although SERPINs are found in a variety of functional on/off sub-forms, customarily they are observed and reported in aggregate. As a result, their influence on disease is missed. Using a new lens of examination, our technology depicts an imbalance of functional SERPIN sub-forms in the cancer population relative to that of a normal population. Consequently, new insights will be extracted into the opportunistic mechanisms that drive cancer pathogenesis and metastatic dissemination, and how those might be unwound therapeutically. Most significantly, the biomarkers in blood we define in our patent application will be paramount to identifying how individuals are uniquely pre-disposed to cancer, how individuals uniquely adapt to the presence of cancer anywhere in the body, and how individuals uniquely respond to medical intervention.

To read the full press release on Stroma Liquid Biopsy™ Patent Application you can click here.